Dominari Holdings releases shareholder update

Dominari Holdings released the following shareholder update: “As disclosed in prior letters and filings, Dominari has completed its transition from a drug development company to a financial services company, complete with a fully registered and rapidly growing broker-dealer subsidiary. With the first full quarter of operating a broker-dealer behind us, I am excited to take this opportunity to update you on our business and provide you with additional insights on how we intend to grow moving forward…. With our recent acquisitions, we currently hold over $700 million in client assets. We will continue to aggressively seek to grow the business through the acquisition of other wealth management teams with assets under management. Additionally, our budding capital markets team has already enjoyed success across a broad spectrum of industries, including in healthcare, biotechnology, industrial and consumer industries… As demonstrated above, we will continue to create a unique blend of traditional wealth management offerings that clients have come to know and trust. In addition, we are creating opportunities for our clients to participate in the leading edge of wealth creation vehicles via our access to pre-IPO companies and other unique alternative financial investments… Our leadership team is comprised of many seasoned veterans from leading Wall Street firms… As for Company structure, we have placed all of the legacy AikidoPharma business into a subsidiary, Aikido Labs LLC. Aikido Labs will continue to monitor and monetize the assets formerly held by AikidoPharma, such as the biotechnology assets and the Company’sholdings in other companies… Management strongly believes that the Company has created a solid platform from which to grow. As evidenced by our publicly filed Form 4s, members of the management team made multiple stock purchase transactions throughout the first, second and third quarters to demonstrate our belief in the Company. “